We include market-access risk ratings in our country reports to help you assess the entire value creation process and develop tailored strategies supported by substantial real-world evidence. This evidence, based on product and customer segments, allows you to gain access and secure markets.
Our comprehensive risk rating model consists of quantitative and qualitative factors, such as total GDP, total population, public and private healthcare expenditure, level of reimbursement and price cuts, and intellectual property mechanisms to assess total market access risk. These collective factors determine a country’s ability and willingness to play for new drugs.
Market access strategies developed on the granular understanding of risk-return relationship (in each country) will help companies gain unique competitive advantage while helping them explore new opportunities.